SYRS Logo

Syros Pharmaceuticals, Inc. (SYRS) 

NASDAQ
Market Cap
$7.15M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
57 of 774
Rank in Industry
43 of 432

Largest Insider Buys in Sector

SYRS Stock Price History Chart

SYRS Stock Performance

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute …

Insider Activity of Syros Pharmaceuticals, Inc.

Over the last 12 months, insiders at Syros Pharmaceuticals, Inc. have bought $4.32M and sold $363,364 worth of Syros Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Syros Pharmaceuticals, Inc. have bought $1.51M and sold $1.96M worth of stock each year.

Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $8M. Haas Jason (Chief Financial Officer) — $161,240. Chee Conley (President & CEO) — $160,680.

The last purchase of 45,344 shares for transaction amount of $76,006 was made by Haas Jason (Chief Financial Officer) on 2024‑09‑12.

List of Insider Buy and Sell Transactions, Syros Pharmaceuticals, Inc.

2024-11-19SaleChief Legal & Compliance Offic
46,657
0.1328%
$0.22$10,3210.00%
2024-11-18SaleChief Development Officer
36,133
0.149%
$0.22$7,9490.00%
2024-11-18SaleChief Medical Officer
12,099
0.0447%
$0.20$2,3820.00%
2024-11-18SaleChief Financial Officer
137,803
0.5433%
$0.21$28,9800.00%
2024-11-18SalePresident & CEO
134,797
0.5049%
$0.20$26,9320.00%
2024-09-12PurchaseChief Financial Officer
45,344
0.1811%
$1.68$76,006+26.11%
2024-09-11PurchasePresident & CEO
50,000
0.2049%
$1.71$85,420-8.10%
2024-09-11PurchaseChief Financial Officer
19,293
0.073%
$1.58$30,446-0.51%
2024-09-10PurchasePresident & CEO
50,000
0.1805%
$1.51$75,260+26.60%
2024-09-10PurchaseChief Financial Officer
35,363
0.1314%
$1.55$54,788+26.60%
2024-06-28Saledirector
34,837
0.1171%
$5.12$178,3650.00%
2024-04-03SaleChief Medical Officer
10,451
0.0393%
$4.95$51,732+0.60%
2024-04-02SaleChief Medical Officer
150
0.0006%
$4.98$747+7.97%
2023-12-21Purchasedirector
904,977
3.271%
$4.42$4M-8.00%
2023-12-12SaleChief Medical Officer
6,287
0.0339%
$4.95$31,121+11.92%
2023-12-06SaleChief Medical Officer
6,287
0.0291%
$3.95$24,834+33.13%
2023-07-31SaleChief Medical Officer
7,348
0.03%
$3.95$29,025+27.89%
2023-07-17SaleChief Scientific Officer
689
0.0025%
$3.50$2,412+42.33%
2022-09-29Purchase
16,932
0.1927%
$6.26$105,955-34.93%
2022-01-05SaleChief Scientific Officer
4,416
0.0068%
$3.47$15,310-75.30%

Insider Historical Profitability

1.43%
AKKARAJU SRINIVASdirector
1786427
6.6577%
$0.2766+15.7%
Chee ConleyPresident & CEO
0
0%
$0.2721
Haas JasonChief Financial Officer
0
0%
$0.2731
NELSEN ROBERT
4637137
17.2818%
$0.2710<0.0001%
ARCH Venture Fund VII, L.P.10 percent owner
4242051
15.8094%
$0.2719<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bain Capital Life Sciences Investors Llc$14.71M10.292.75M0%+$01.18
Artal Group S A$13.4M9.372.51M0%+$00.06
Adage Capital Partners Gp L L C$11.08M7.752.07M0%+$00.02
Samsara Biocapital Llc$9.56M6.681.79M0%+$01.49
Avidity Partners Management Lp$8.95M6.261.67M0%+$00.34
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.